Zhitong Finance App learned that Guojin Securities released a research report stating that it maintains the “buy” rating of Ricoh Bio-B (02179). Considering the continuous advancement of its future product pipeline and clinical trials, R&D investment is expected to continue to increase. It is expected to achieve net profit of -723/-5.16/-348 million yuan in 2022-24. On December 23, the company announced that the phase II sequential strengthening clinical trial of the recombinant two-component COVID-19 vaccine RecoV had achieved positive results.

According to the report, the neutralizing antibody levels for the Omicron mutants BF.7 and Ba.2.75 induced by the company's RECoV sequential intensification were significantly superior to the results of the mRNA vaccine group. After 14 days of vaccination, the GMTs for the neutralizing antibodies of the Omicron variant BF.7 in the RecoV group and mRNA vaccine group were 6549.1 and 4529.6 respectively, and the GMT of the Recov group was significantly higher than that of the mRNA vaccine group. Furthermore, neutralizing antibodies induced by the RECOV group were 30.8 times higher than the baseline, significantly higher than the mRNA vaccine (22.7 times). The RecoV group's neutralizing antibody against the omicjone variant BF.7 was only 2.5 times lower than the prototype strain, showing excellent cross-neutralization effects. Previously, the company RecoV also showed excellent effects on the true virus neutralizing antibody levels of the Omicron variant Ba.5 and Ba.2 and the prototype strain. Currently, the company is submitting product listing applications to domestic regulatory authorities on a rolling basis.